HIT to lead chemistry under performance area 2 of ID/IQ contract no. HHSN271201800001I
Ended Awarded Last action
- Contract number
- 75N95022F00007
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,796,372
Award facts
- Opportunity
-
- NIHNINDS2205 Solicitation number
- Contract value 100% obligated
- $1,796,372.11 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $611,149 | |
| Supplemental Agreement for work within scope | $456,391 | |
| Other Administrative Action | $0 | |
| Original award | $728,832 |
About this award
This is a delivery order under indefinite-delivery/indefinite-quantity (IDIQ) contract HHSN271201800001I awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to Curia Global Inc. (doing business as Amri). The $1,796,372.11 contract is for "HIT TO LEAD CHEMISTRY UNDER PERFORMANCE AREA 2" of the Medicinal Chemistry Support Program for Therapeutic Development. Curia, a leading global contract development and manufacturing organization (CDMO), will provide a range of pharmaceutical research and development services to NINDS, including medicinal chemistry, process chemistry, and GMP manufacturing. This award builds on Curia's extensive experience supporting various NIH institutes and federal agencies in areas such as neurology, infectious diseases, and substance abuse research and development. No set-aside designation was used for this contract.
Quick answers
Who was awarded contract 75N95022F00007?
75N95022F00007 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 27, 2022.
How much is contract 75N95022F00007 worth?
The government has obligated $1,796,372 on 75N95022F00007.
Which agency awarded contract 75N95022F00007?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022F00007, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95022F00007 an order under another contract?
Yes. 75N95022F00007 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95022F00007 competed?
The extent of competition for 75N95022F00007 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award